Topotecon vs PLD aloneProgression free survival (platium‐sensitive) · patients with EOC1 finding from 1 reviewTopotecan for ovarian cancer 2008 · Cochrane Headline outcomes onlyno estimate extracted1 study · 220 participantsModerate
Topotecon vs PLD aloneProgression free survival (platium‐resistant) · patients with EOC1 finding from 1 reviewTopotecan for ovarian cancer 2008 · Cochrane Headline outcomes onlyno estimate extracted1 study · 220 participantsModerate